Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), announced today that it will attend and exhibit at the Wound Care Seminar: Clinical and Economical Realities in Boston. This seminar is presented by HMP Communications, the publishers of OWM, WOUNDS, Today's Wound Clinic, Podiatry Today and producers of the Symposium on Advanced Wound Care. The seminar will be attended by podiatrists, nurses, PT's, nursing home administrators, dieticians, and pharmacists who care for patients with wounds. The focus is on the clinical and economic perspective of wound care delivery in various sites of service.

"This seminar is an excellent opportunity for us to present our advanced wound care product, CellerateRx®," states Cathy Bradshaw, President of Wound Care Innovations. "CellerateRx® is FDA cleared for use on all wound types except for 3rd degree burns and is effective in all wound phases. It is biodegradable so it does not need to be removed from the wound and reapplication is 3 times per week or as needed. Fewer required dressing changes translates to lower staffing and material costs for the healthcare industry, for which wounds are becoming a major expense. In the United States alone, when additional costs associated with wound care morbidity are factored in, the total costs soar to over an estimated 200 billion annually. CellerateRx®'s performance and cost effectiveness is key element in today's healthcare environment. Being in attendance here allows us to present this information to a defined wound care market segment."

Additionally, Wound Care Technologies is continuing its plans to do expanded clinical research and evidence based studies on the mechanisms by which CellerateRx® affects factors crucial for wound healing. More details on this will be announced shortly.

About Wound Management Technologies, Inc.:

Wound Management Technologies, Inc. (OTCBB: WNDM - News), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company's Website at www.CellerateRx.com .

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.